{
  "id": "532f05a5d6d3ac6a34000025",
  "type": "summary",
  "question": "What is the effect of ranolazine in diastolic heart failure?",
  "ideal_answer": "Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current. Ranolazine is an innovative anti-ischemic and antianginal agent that reduces the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. Furthermore, ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/17027025",
    "http://www.ncbi.nlm.nih.gov/pubmed/18439620",
    "http://www.ncbi.nlm.nih.gov/pubmed/24251065",
    "http://www.ncbi.nlm.nih.gov/pubmed/7873471",
    "http://www.ncbi.nlm.nih.gov/pubmed/22343711",
    "http://www.ncbi.nlm.nih.gov/pubmed/19333133",
    "http://www.ncbi.nlm.nih.gov/pubmed/19403851",
    "http://www.ncbi.nlm.nih.gov/pubmed/22465693",
    "http://www.ncbi.nlm.nih.gov/pubmed/21538388",
    "http://www.ncbi.nlm.nih.gov/pubmed/20924097",
    "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
    "http://www.ncbi.nlm.nih.gov/pubmed/23596505",
    "http://www.ncbi.nlm.nih.gov/pubmed/19752362"
  ],
  "snippets": [
    {
      "text": "Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21538388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ranolazine is an innovative anti-ischemic and antianginal agent that inhibits the late Na current, thereby reducing the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. In addition, ranolazine seems to exert beneficial effects on diastolic cardiac function. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22343711",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Diastolic dysfunction could be reversed by ranolazine, probably resulting from a direct effect on myofilaments, indicating that cardiac oxidative stress may mediate diastolic dysfunction through altering the contractile apparatus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22343711",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ranolazine (10 microM) significantly reduced the PC-induced increase in LVEDP by 72 +/- 6% (n = 6, p < 0.001), reduced left ventricular wall stiffness, and attenuated the PC-induced increase of CPP by 53 +/- 10% (n = 6-7, p < 0.05). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19403851",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Ranolazine, a specific inhibitor of late INa, reduces Na influx and hence ameliorates disturbed Na and Ca homeostasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19333133",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "New clinical and experimental studies even point to potential antiarrhythmic effects, beneficial effects in diastolic heart failure, and under hyperglycemic conditions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19333133",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054144",
    "http://www.biosemantics.org/jochem#4202863"
  ]
}